All

What are you looking for?

All
Projects
Results
Organizations

Quick search

  • Projects supported by TA ČR
  • Excellent projects
  • Projects with the highest public support
  • Current projects

Smart search

  • That is how I find a specific +word
  • That is how I leave the -word out of the results
  • “That is how I can find the whole phrase”

Efficacy and Toxicity of Panitumumab After Progression on Cetuximab and Predictive Value of MiR-31-5p in Metastatic Wild-type KRAS Colorectal Cancer Patients

The result's identifiers

  • Result code in IS VaVaI

    <a href="https://www.isvavai.cz/riv?ss=detail&h=RIV%2F00209805%3A_____%2F16%3AN0000071" target="_blank" >RIV/00209805:_____/16:N0000071 - isvavai.cz</a>

  • Alternative codes found

    RIV/00216224:14740/16:00087634 RIV/00216208:11110/16:10327760 RIV/00216208:11150/16:10327760 RIV/61989592:15110/16:33161335 and 3 more

  • Result on the web

    <a href="https://ar.iiarjournals.org/content/anticanres/36/9/4955.full.pdf" target="_blank" >https://ar.iiarjournals.org/content/anticanres/36/9/4955.full.pdf</a>

  • DOI - Digital Object Identifier

    <a href="http://dx.doi.org/10.21873/anticanres.11063" target="_blank" >10.21873/anticanres.11063</a>

Alternative languages

  • Result language

    angličtina

  • Original language name

    Efficacy and Toxicity of Panitumumab After Progression on Cetuximab and Predictive Value of MiR-31-5p in Metastatic Wild-type KRAS Colorectal Cancer Patients

  • Original language description

    Background: In metastatic colorectal cancer (mCRC), panitumumab is generally considered to be ineffective after the progression on cetuximab therapy. However, few studies have demonstrated that a small subset of mCRC patients may benefit from panitumumab in this setting. Patients and Methods: In our study, wild-type KRAS mCRC patients, enrolled into the nationwide Czech registry CORECT between January 2007 and December 2012, were screened for panitumumab therapy after progression on cetuximab. Results: We identified 26 mCRC in the registry with well documented progression on cetuximab in combination with irinotecan-based chemotherapy (FOLFIRI or irinotecan alone) who received panitumumab monotherapy. Partial response (PR) was achieved in 3 (11.5%) patients and stable disease (SD) in 7 (26.9%) patients after 8 weeks of therapy. Thirteen (50.0%) patients had evidence of progressive disease (PD) and in 3 (11.5%) cases response was not available. Furthermore, we confirmed that higher expression levels of newly described biomarker, miR-31-5p, in tumor are significantly associated with shorter progression-free survival (PFS) in patients treated with cetuximab (p=0.038); however, we did not observe association between miR-31-5p and response to panitumumab in mCRC patients after progression on cetuximab. Conclusion: It remains possible that a subset of mCRC patients may benefit from panitumumab after progression on cetuximab.

  • Czech name

  • Czech description

Classification

  • Type

    J<sub>imp</sub> - Article in a specialist periodical, which is included in the Web of Science database

  • CEP classification

  • OECD FORD branch

    30204 - Oncology

Result continuities

  • Project

  • Continuities

Others

  • Publication year

    2016

  • Confidentiality

    S - Úplné a pravdivé údaje o projektu nepodléhají ochraně podle zvláštních právních předpisů

Data specific for result type

  • Name of the periodical

    Anticancer research

  • ISSN

    0250-7005

  • e-ISSN

  • Volume of the periodical

    36

  • Issue of the periodical within the volume

    9

  • Country of publishing house

    GR - GREECE

  • Number of pages

    5

  • Pages from-to

    4955-4959

  • UT code for WoS article

    000384001800083

  • EID of the result in the Scopus database

    2-s2.0-84991696540